Share
EAST LANSING, Mich. — Michigan Rise is pleased to formally introduce Esperovax, developer of the Egress RD™ Oral Biologics platform, to its growing portfolio.
The Plymouth, Michigan-based company has developed a novel, mRNA-based oral vaccine platform that will enable large scale production and distribution of shelf stable vaccines and biological therapeutics. Their platform enables prevention and treatment of some of the world’s deadliest diseases, including COVID-19, at a fraction of the cost of current injection-based therapies.
“We are grateful to Michigan Rise for recognizing the importance of our work,” said David O’Hagan, Ph.D., Esperovax Founder, President and CEO. “It will play a role in our ability to provide rapid, painless, and inexpensive biological medicines that make a significant impact on global health.”
Esperovax’s Egress RD™ Oral Biologics platform utilizes common baker’s yeast as a novel mRNA vaccine delivery technology. This technology means billions of doses could potentially be manufactured in less than a month. This oral vaccine will not require costly purification processes, cold storage, or delivery devices such as syringes. Each dose can be economically produced and self-administered via pill or edibles.
“We are pleased to partner with Esperovax with value-added capital to help the company realize its mission, the importance of which has been exacerbated by the current global pandemic,” said Prem Bodagala, Director at Michigan Rise.